Lumida
/CAPR
⌘K
Capricor Therapeutics Inc

Capricor Therapeutics Inc

CAPR
$8.37USD+0.84%+0.07 today

MARKET CAP

486.6M

P/E (TTM)

FWD P/E

DAY RANGE

$8 – $9

52W RANGE

$3
$40

AI Summary

Stalk
StalkMedium

CAPR remains in a deep Stage 4 decline with all moving averages sloping downward and price trading below key MAs. Extreme oversold readings suggest a tactical bounce, but the long-term trend stays bearish. Mean-reversion eligibility forces a bullish medium-term bias, permitting only countertrend entries. Short-term execution is deferred until we see support confirmation or an initial relief rally into falling EMAs.

  • Share price jumped 97% post-FDA application amendment; Cantor Fitzgerald set $28 target.
  • HOPE-3 data showed Deramiocel slowed DMD upper-limb decline by 54%.
  • Q2 operating expenses rose 55% YoY to $42.9 M, driving a $40.7 M net loss ($0.70/share).
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2020FY 2021FY 2022FY 2023FY 2024TREND
Sales, Adj.$310,250$244,898$2.6M$25.2M$22.3M
YoY %-69.1%-21.1%+941.8%+886.8%-11.5%
P / Sales172.1x276.2x37.0x5.4x21.8x
EV / Sales87.5x174.5x48.3x6.3x22.4x
Gross Profit, Adj.$310,250$244,898$2.6M$25.2M$22.3M
YoY %-69.1%-21.1%+941.8%+886.8%-11.5%
Margin %100.0%100.0%100.0%100.0%100.0%
EV / Gross Profit87.5x174.5x48.3x6.3x22.4x
EBITDA, Adj.$-13.5M$-20.7M$-29.2M$-23.0M$-41.1M
YoY %-79.1%-52.8%-40.9%+21.1%-78.8%
Margin %-4366.2%-8449.5%-1143.0%-91.4%-184.7%
EV / EBITDA-2.0x-2.1x-4.2x-6.9x-12.1x
EBIT$-13.7M$-20.9M$-29.7M$-24.1M$-42.6M
YoY %-77.0%-52.9%-41.8%+18.9%-76.8%
Margin %-4412.6%-8549.9%-1163.9%-95.6%-191.1%
EV / EBIT-2.0x-2.0x-4.1x-6.6x-11.7x
Net Income$-13.7M$-20.0M$-29.0M$-22.3M$-40.5M
YoY %-78.7%-46.6%-44.9%+23.2%-81.6%
Net Margin-4401.9%-8175.9%-1137.4%-88.5%-181.7%
EPS (GAAP)-$0.88-$0.87-$1.18-$0.83-$1.15
YoY %+57.3%+1.1%-35.6%+29.7%-38.6%